BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

I just returned from a five day trip to India at the invitation of our distributor Kirloskar Technologies (KTPL). A special thanks to the planning and support of Mr. Ketan Desai, President of the Oncology Business at KTPL, for arranging the site visits and taking such good care of us. India is a very large market and can play an important role for growth of Pyrexar. To put the Indian market into perspective, the country represents just under 18% of the world population (1.34 billion population) packed into a land mass 1/3 the size of the US (323 million people). Treating the nation's cancer patients is a serious challenge.

Sasi Sekhar, KTPL Service Manager | Ketan Desai, President Oncology Business, KTPL | Dr. Geeta S Narayanan, Vydehi Institute | Mark Falkowski, CEO, Pyrexar Medical | Dr. Lokesh Viswanath | Dr. R. Vinaykumar

Mr. Sayan Bhattacharya | Dr. Jigna Bhattacharya, Assoc. Professor, Gujarat Cancer & Research Institute | Mark Falkowski, CEO, Pyrexar Medical | Ketan Desai, President Oncology Business, KTPL

Mark Falkowski, CEO, Pyrexar Medical | Dr. Nagraj Huilgol, Chief Radiation Oncologist, Nanavati Super Specialty Hospital | Ketan Desai, President Oncology Business, KTPL

Dr. Huilgol currently practicing at Nanavati. "Don't let the quaint exterior fool you, this is as modern a facility as any I have visited in the US" says Mark Falkowski

previous arrow
next arrow
ArrowArrow
Slider


The journey took us down the western coast of India where we visited with several key hospitals targeted to introduce our radiative hyperthermia product line to the country. From Ahmedabad in the Northwestern state of Gujarat, to the coastal city of Mumbai in Maharashtra, to the southern city of Bangalore in Karnataka.  Information was well received, but they all asked the same question "Where have you been". That question is a little difficult to answer as our products are well established in European nations, in the US , China and growing rapidly on the Korean peninsula.

Where have you been? Why isn't Pyrexar in India?

Pyrexar has seen tremendous growth in the last three years. The regulatory requirements to enter each new country are rigorous and we have been working quickly to bring proven hyperthermia treatment to the world. As we start filling the void, lesser technologies are pushed aside and replaced. The plain truth to why we are not active in India is that we did not have solid distribution partners, until now. Kirloskar Technologies has the technical understanding, product depth and reach, and a service team that can handle our product line. With this partnership in place, it is possible to bring our systems to market in India.

One of the highlights of the trip was my meeting with Dr. Nagraj Huilgol. As you may know, Dr. Huilgol is a hyperthermia advocate and researcher with more than 100 publications in national and international journals. He was lead researcher in a phase III clinical study on head and neck cancer using capacitive hyperthermia. His CV includes Chief Editor of the Journal of Cancer Research and Therapeutics (JCRT) and a member of editorial boards of the Indian Journal of Cancer, Indian Journal of Head and Neck Cancer, International Journal of Hyperthermia and official journal of ASHO, ESHO and NAHO. Having this well known hyperthermia expert as a luminary will help usher hyperthermia into India.

 

We are proud to announce the signing of Finggal Link Co. Ltd, headquartered in Tokyo, as our new distributor in Japan. Through the combined efforts of Mr. Masaaki Inoue of Advanced Medical and the regulatory group at Finggal Link, we hope to reinvigorate the product line in Japan.

In the 1980's and 1990's, there were approximately twenty BSD-1000 units installed in Japan. The BSD-1000 is the predecessor to the products we have today. In 1993, the sales distributor for Japan was disolved, leaving a product registration void that was never re-established. With this new effort, we hope to introduce the new Pyrexar product line and revive the use of hyperthermia for the treatment of cancer in Japan.

finggal link signingMasaaki Nagone-CEO, Finggal Link; Mark Falkowski - CEO, Pyrexar Medical; Kenji Hirayama - Director, Int'l Affairs and RA/QA, Finggal Link
Dr. Tetsuya Furukawa - Director, Medical Division, at Finggal Link, will head the clinical introduction efforts at major hospitals throughout the country. A special thanks to Dr. Hayes and the thermal oncology team at Gamma West Cancer Services in Salt Lake City for allowing Dr. Furukawa to observe a Head and Neck Brachytherapy and Hyperthermia treatment at the St. Mark's location. Gamma West is a great asset to the medical community in Utah, and throughout the intermountain region, providing lifesaving and life changing procedures for cancer patients.

Finggal link at gamma westMasakki Innoue - Advanced Medical Systems; Dr. John Hayes - Gamma West Cancer Services; Paul Turner - Pyrexar Medical; Dr. Tetsuya Furukawa - Finggal Link

We want to acknowledge all the speakers for their participation at First International Conference of the Polish Society for Hyperthermic Oncology.  It was an amazing event.  Special thanks to the dedicated team at HT systems for creating such a dynamic conference and for re-energizing hyperthermia in Poland. And to the co-sponsors of the event for their support of the meeting. Pyrexar Medical strives to support hyperthermia (the treatment of cancer with heat) education and research around the globe.

Distribution Partner HT Systems
Dariusz Droś, CEO of HT Systems and Mark Falkowski, CEO of Pyrexar Medical

BSD-2000 Scale Model
HT Systems commissioned a 1/3 scale model of the BSD-2000 Sigma Base with the Sigma Ellipse Applicator

Pyrexar Represented
HT Systems is the exclusive distributor of Pyrexar Medical Hyperthermia Systems in Poland

Meeting Well Attended
A large group of researchers and clinicians attended the event at the Hotel Rezydencja Luxury, Piekary Slaskie, Poland

previous arrow
next arrow
Slider

The lectures were professionally recorded and are in the editing process. The PTHO has started a Youtube Channel which will be hosting the video presentations of the speakers listed below.

Speaker Video Lecture Background
Prof. Niloy R. Datta, MD, DNB, CCST (CH) Play Video "Overview of meta-analysis clinical trials in head neck cancers / recurrent breast tumours / locally advanced cancer cervix" 
[Language: English]
Senior Consultant and Head, Radiation Oncology Research Programme, Centre of Radiation Oncology KSA-KSB, Kantonsspital Aarau AG, Aarau, Switzerland
Dr. Sc. Hana Dobsicek Trefna,PhD (S) Play Video "Quality assurance in hyperthermia treatments"
[Lecture: English]
Assistant professor in the Biomedical electromagnetics research group and an expert in systems and focusing algorithms for microwave hyperthermia treatment of deep-seated tumors. Her work aims at the clinical introduction of hyperthermia in Sweden, developing a UWB hyperthermia system for treatment of Head and Neck tumors and exploring the possibility of hyperthermia treatment of brain tumors in children.
Dr. med. Boris Hübenthal, MD, PhD (CH) Play Video "Case Reports from the Center of Integrative Oncology ZIO Zurich"
[Language: Polish]
Medical Director of the Center of Integrative Oncology ZIO in Zürich Switzerland, Chairman of the European society for integrative oncology ESIO eV. Principle investigator of the database project www.bestcase-oncology.com
Prof. Rolf Issels, MD, PhD (D) Play Video "Up-date on clinical trials combining regional hyperthermia with chemotherapy" presented at the PTHO Confrence "
[Language: English]
Head of the Clinical Cooperation Group Hyperthermia
Researcher at the Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Dr. Jacek Kabut, MD, PhD (PL) Play Video "The treatment of bladder cancer combined with regional hyperthermia - case report" [Language: Polish] Specialist of Internal Medicine and Oncology. Chief Assistant of the Oncology Department in the Regional Specialist Hospital in Rybnik.
Oncology consultant in the Regional Hospital of Pulmonary Diseases in Wodzisław-Śląski Wilchwach.
Member of the Polish Society for Clinical Oncology, Polish Society for Experimental and Clinical Immunology and of Polish Society for Hyperthermic Oncology.
Dr. Dorota Kazberuk, MD (PL) Play Video "Deep tissue hyperthermia in oncological gynaecology in Białystok Cancer Center"
[Language: Polish]
Radiation Oncologist in the Radiation and Brachytherapy Department and Brachytherapy Coordinator of the Białystok Cancer Centre. Member of the supervisory committee of the Polish Brachytherapy Society (PTB). Regional Branch President of the Polish Oncology Society of Podlasie.
Prof. Wiesław Kozak, PhD (PL) Play Video "Fever Biology"
[language: Polish]
Full Professor at the Nicolaus Copernicus University in Toruń, Poland,  former Dean of Biology and Environmental Sciences, Head of Immunology Department
Dr. Andrzej Kukiełka, MD, PhD (PL) Play Video  "Rescue brachytherapy combined with interstitial hyperthermia in local relapse of prostate cancer after radical radiation therapy - prospective study phase II - current state of research"
[Language: Polish; Slides: English]
Radiation Oncologist in NU-MED Cancer Diagnostics and Therapy Centre in Zamość 
Member of European Society of Hyperthermic Oncology (ESHO)
Member of the Review Panel of the Polish Brachytherapy Society (PTB)
Prof. Urszula Mazurek, MD, PhD (PL) Play Video "Heat shock proteins in hyperthermia applied in oncology"
[Language: Polish; Slides: English]
Head of Department of Molecular Biology at the Silesian University of Medicine, Member of Scientific Committee in the Biotechnology Center of the Silesian University of Technology.
Dr. Med. Michal Niksa Play Video "Operation of the BSD-2000. Experiences made in Cancer Centre of Białystok". 
[language: Polish]
A member of the Department of Radiotherapy with the Brachytherapy Department of the Białystok Cancer Center
Dr. markus Notter, MD, PhD (CH) Play Video "Low dose re-irradiation & hyperthermia in extended local recurrent breast cancer : perspectives and challenges"
[Language: English]
Radiation oncologist in the Lindenhofspital in Bern (CH), vice-president of the Berne Foundation against Cancer (Ligue Bernoise Contre le Cancer), member of the board of the Swiss Cancer League.
Prof. Elisabeth Repasky, MD, PhD (USA) Play Video "Temperature Matters: Chasing an elusive evidence-based rationale for hyperthermia in the cancer clinic"
[Language: English]
Professor of Oncology, William Huebsch Professor of Immunology and Program Leader for the Cell Stress and Biophysical Therapies Program at Roswell Park Cancer Institute in Buffalo, NY.
Dr. Wacław Śmiertka, MD, PhD (PL) Play Video "Recommendations of PTHO for use of hyperthermia in selected cancer diseases"
[Language: Polish; Slides: English]
Gynaecologic Oncologist in Warsaw Cancer Institute
Dr. Bartosz Urbański, MD, PhD (PL) Play Video "The oncologic hyperthermia" presented during the conference of PTHO"
[Language: Polish]
Radiation Oncologist in Great-Poland Cancer Institute, Poznan
Dr. Jacoba van der Zee, PhD (NL) Play Video "Results of randomized trials comparing treatments with or without hyperthermia"
[Language: English]
Researcher in the field of Hyperthermia at the Dept. of Radiation Oncology, Erasmus University Rotterdam, Rotterdam
Prof. Gerard C. van Rhoon, PhD, (NL) Play Video "Current Technology for Hyperthermia Treatment"
[Language: English]
Professor in Erasmus MC Cancer Institute, head of Hyperthermia Unit, president of the European Society for Hyperthermic Oncology (ESHO)
Dr. rer. nat. Alexander von Ardenne, Dipl.-Phys. (D) Play Video  "Non-oncological hyperthermia and a new immunological road to attack cancer" presented during the conference of PTHO"
[Language: English]
Head of the "Von Ardenne Institute‎ of Applied Medical Research GmbH"
Prof. Zeljko Vujaskovic, MD, PhD (USA) Play Video "Hyperthermia and Immunotherapy in Cancer Treatment: Rational and Clinical Directions"
[Language: English]
Professor at the University of Maryland School of Medicine, USA. Head of the Division of Translational Radiation Sciences in the Department of Radiation Oncology
Prof. Holger Wehner, MD, PhD (D) Play Video "Extreme whole body hyperthermia: risks and opportunities"
[Language: English]
President of German Hyperthermia Society.  Medical director in the Gisunt Klinik - Integrative Medicine and International Hyperthermia Centre. Specialist for hyperthermia since 30 years.

 


We are excited to announce the commissioning of a BSD-2000 3D/MR "Universal" System at Grosshardern University Hospital in Munich Germany. 

LMU (Ludwig Maximilians University of Munich in Großhadern) has been a pioneer in cancer treatment with hyperthermia.  The hospital has treated over 15,000 patient treatments with hyperthermia, many of them with Soft Tissue Sarcoma tumors. This facility was part of a phase III clinical study which illuminated the long-term survival benefits of adding hyperthermia to chemotherapy.  LMU is also at the center of the HEAT (Hyperthermia European Adjuvant Trial) study, a randomized, dual-arm trial for pancreatic cancer using chemotherapy plus hyperthermia. 

The BSD-2000 3D/MR uses MR imaging to visualize temperature in the treatment area. MR images are taken during the hyperthermia treatment and proprietary software creates a three-dimensional (non-diagnostic) representation of the heating zone in the body. With this information, the operator can easily adjust the heating zone in 3 dimensions to ensure that the tumor area receives the maximum thermal dose. Above is an excellent product video produced by Sennewald Medizintechnik GmbH, the innovators of the SigmaVision software and Pyrexar’s distributor in Germany.

montage for munich

The Sigma Eye MR applicator uses the existing MR patient support table and can be removed and stored when not in use, leaving the MR free for general imaging. The complete system package includes a Dodek 12-channel RF amplifier (positioned in the equipment room), the Sigma Eye MR applicator,  a water circulation system that provides temperature-controlled deionized water to the applicator bolus (seen in blue), an 8-channel motor-controlled temperature box (used to verify thermal accuracy during treatment), and a computer system with control software. 

The BSD-2000 3D/MR fits most 1.5 Tesla, 60cm bore (or greater) MRI systems on the market. Our system runs at 100MHz providing deep regional hyperthermia to any depth in the body. The applicator is capable of treating up to 95 percentile patient size based on available world data.

Scheduled release for sale - April 2018.